Clinical Cases in Pharmacology Clinical Cases  ·  Psychiatry III  ·  Schizophrenia Spectrum and Other Psychotic Disorders
Psychiatry III, Case 0017 — Schizophrenia

Delusional Disorder: Pushing Pharmacotherapy vs. Functional/Supportive Focus

Antipsychotics have only modest evidence in delusional disorder, and he doesn't believe anything is wrong with him to begin with. Pushing medication and focusing on function instead are both genuinely defensible paths.

Abbreviations, terms, and other agents mentioned in this case SGA — second-generation antipsychotic
Presentation

W.P., a 58-year-old man, spent over two decades running a small consulting business with the same partner before the relationship soured and eventually dissolved into what W.P. now describes as an ongoing campaign against him — a rupture his daughter dates to roughly three years ago, right around when the fixed beliefs first appeared. He has held a fixed, encapsulated belief for approximately three years that this former business partner is orchestrating a long-running campaign to ruin his reputation, involving falsified documents and paid informants among his neighbors.

Outside this specific belief system, his functioning is largely intact: he manages his own finances, maintains a long-term relationship with his adult daughter, who accompanies him to this visit worried but unsure what to do, and holds a steady part-time consulting job of his own now, though he has become increasingly isolated as he avoids people he believes are involved in the conspiracy. His daughter says he used to have a wide circle of friends from his old business years and has watched that circle shrink to almost no one over the past three years.

Delusional disorder differs from schizophrenia in exactly this way — the delusion is often encapsulated, without the broader disorganization or negative symptoms seen in schizophrenia, and functioning outside the delusion's specific domain can remain remarkably preserved for years. Antipsychotic trials in delusional disorder show only modest average efficacy, and W.P., like most patients with this diagnosis, has no insight that anything is wrong; he is here only because his daughter asked him to come, not because he believes he needs treatment. Pushing pharmacotherapy on a patient without insight raises real questions about whether it will even be taken as prescribed, while a primarily supportive, function-focused approach risks doing nothing about a belief system that is visibly narrowing his life.

W.P. · 58 No insight, preserved function
History
Fixed, encapsulated delusional belief system, approximately 3 years duration
Function outside delusion
Independent finances, steady part-time work, sustained relationship with daughter
Insight
None; attends only at his daughter's request, does not believe treatment is needed
Social trajectory
Increasing isolation as he avoids individuals he believes are involved
Prior treatment
No prior psychiatric treatment or medication trials

How hard to push medication

Attending Psychiatrist Opening

I'd actually push harder than we usually do in delusional disorder. Muñoz-Negro and colleagues' 2020 systematic review, the best pooled data specifically on antipsychotics in this diagnosis, found roughly a third of patients achieve a good response — modest, but real, and his isolation has been getting measurably worse for three years. Waiting for insight he may never develop, while his world keeps shrinking, isn't neutral. I'd frame today's visit around a real recommendation to try medication, not just an option laid on the table.

Psychiatric Pharmacist Response

That's the same number I'd cite, and I'd read it the other direction. Roughly a third responding means roughly two-thirds don't — and he has no insight, and is only here because his daughter asked him to come. A prescription he experiences as pressure is, realistically, a prescription he stops taking the moment he leaves, and a visit that felt like pressure is a visit he might not repeat. "Modest but real" doesn't settle this on its own; it also means the actual expected benefit has to be weighed against a real chance of damaging the one relationship that got him in the door at all.

Primary Care Physician Final

You're both reading the same real number toward different, defensible actions, and I don't think this needs to be a split-the-difference compromise so much as a genuinely different third move: offer medication clearly, once, without repeating the pitch if he declines — that's still a real recommendation, not an option buried in a list — but center today's actual conversation on the isolation, since that's the piece he might engage with regardless of what he decides about the medication.

Regimen selected
Antipsychotic Trial — Offered, Not Mandated
Second-Generation Antipsychotic · Patient declined for now
Offered directly with honest disclosure of its modest average efficacy in delusional disorder; not pursued further today given W.P.'s lack of insight and explicit reluctance, to avoid damaging his willingness to keep attending.
Where this was left

Agreed: today's visit closes with a supportive, function-focused plan — regular follow-up centered on his social isolation and daily functioning, medication left explicitly on the table but not pursued over his objection.

Left genuinely unresolved: whether a future visit should revisit medication more assertively if his isolation continues to worsen, or whether pushing harder at that point risks losing his engagement entirely — the team did not settle this in advance, agreeing instead to reassess as his daughter reports back over the coming months.

Educational content only — a composite teaching case, not a real patient encounter or a substitute for clinical guidance. About These Cases →